Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BMRN 
Biomarin Pharmaceutical Inc (BMRN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/21/2025: BMRN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
29 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $94.8
1 Year Target Price $94.8
| 16 | Strong Buy |
| 7 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.52% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/21/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.23B USD | Price to earnings Ratio 15.7 | 1Y Target Price 94.8 |
Price to earnings Ratio 15.7 | 1Y Target Price 94.8 | ||
Volume (30-day avg) 29 | Beta 0.33 | 52 Weeks Range 51.56 - 73.51 | Updated Date 10/21/2025 |
52 Weeks Range 51.56 - 73.51 | Updated Date 10/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-27 | When Before Market | Estimate 0.8233 | Actual - |
Profitability
Profit Margin 21.45% | Operating Margin (TTM) 33.55% |
Management Effectiveness
Return on Assets (TTM) 7.5% | Return on Equity (TTM) 11.62% |
Valuation
Trailing PE 15.7 | Forward PE 10.83 | Enterprise Value 9841992377 | Price to Sales(TTM) 3.34 |
Enterprise Value 9841992377 | Price to Sales(TTM) 3.34 | ||
Enterprise Value to Revenue 3.21 | Enterprise Value to EBITDA 10.54 | Shares Outstanding 192014601 | Shares Floating 178057060 |
Shares Outstanding 192014601 | Shares Floating 178057060 | ||
Percent Insiders 0.78 | Percent Institutions 99.03 |
Upturn AI SWOT
Biomarin Pharmaceutical Inc
Company Overview
History and Background
BioMarin Pharmaceutical Inc. was founded in 1997. It focuses on developing and commercializing therapies for serious and life-threatening rare genetic diseases. BioMarin has grown through internal research, acquisitions, and partnerships.
Core Business Areas
- Genetic Diseases: Develops and commercializes therapies for genetic diseases such as phenylketonuria (PKU), mucopolysaccharidosis (MPS), and achondroplasia.
Leadership and Structure
The CEO is Alexander Hardy. The company has a typical corporate structure with departments focused on R&D, commercial operations, finance, and manufacturing.
Top Products and Market Share
Key Offerings
- Kuvan/Palynziq: Kuvan and Palynziq are for the treatment of phenylketonuria (PKU). Market share is significant in the PKU treatment landscape. Revenue was approximately $425M in 2023. Competitors include synthetic substitutes that also treat this disease.
- Voxzogo: Voxzogo is for the treatment of achondroplasia, the most common form of dwarfism. Competitors may include investigational therapies from other companies. Revenue in 2023 was approximately $570 million
Market Dynamics
Industry Overview
The rare disease market is characterized by high unmet needs, orphan drug designations, and premium pricing. The market is growing due to increased diagnosis rates and advancements in gene therapies.
Positioning
BioMarin is a leader in the rare disease space, with a strong portfolio of approved therapies and a robust pipeline. Its competitive advantage lies in its expertise in enzyme replacement therapies and gene therapies.
Total Addressable Market (TAM)
The TAM for rare disease therapies is estimated to be over $200 billion. BioMarin is well positioned to capture a significant portion of this market through its existing products and pipeline.
Upturn SWOT Analysis
Strengths
- Strong portfolio of approved therapies
- Expertise in rare disease drug development
- Robust pipeline
- Established commercial infrastructure
- Orphan drug designations providing market exclusivity
Weaknesses
- High R&D costs
- Reliance on a limited number of products
- Regulatory risks associated with drug approvals
- Competition from other companies developing rare disease therapies
Opportunities
- Expansion into new rare disease indications
- Development of gene therapies
- Strategic partnerships and acquisitions
- Geographic expansion
- Increased awareness and diagnosis of rare diseases
Threats
- Competition from other rare disease companies
- Pricing pressures from payers
- Clinical trial failures
- Changes in regulatory requirements
- Patent expirations
Competitors and Market Share
Key Competitors
- SGEN
- AMGN
- VRTX
Competitive Landscape
BioMarin competes with other pharmaceutical companies developing therapies for rare diseases. Its advantages include its established commercial infrastructure and expertise in enzyme replacement and gene therapies. Disadvantages include their competition in market share by the larger companies such as Amgen.
Major Acquisitions
Prosensa Therapeutics
- Year: 2014
- Acquisition Price (USD millions): 840
- Strategic Rationale: Acquisition for Prosensa's drisapersen drug, which was focused on Duchenne Muscular Dystrophy.
Growth Trajectory and Initiatives
Historical Growth: BioMarin has experienced significant growth in revenue over the past decade, driven by the commercialization of new products.
Future Projections: Analysts project continued revenue growth, driven by Voxzogo and pipeline products. Profitability is expected to improve as revenues scale.
Recent Initiatives: BioMarin is focused on advancing its gene therapy pipeline, expanding its commercial presence in key markets, and pursuing strategic acquisitions.
Summary
BioMarin is a strong player in the rare disease market, with a diverse portfolio of approved therapies and a robust pipeline. Its financial performance is solid, but R&D expenses remain high. BioMarin needs to navigate competitive pressures and regulatory risks effectively to maintain its growth trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- BioMarin Pharmaceutical Inc. SEC Filings
- Company Investor Relations
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomarin Pharmaceutical Inc
Exchange NASDAQ | Headquaters San Rafael, CA, United States | ||
IPO Launch date 1999-07-23 | President, CEO & Director Mr. Alexander Hardy | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3040 | Website https://www.biomarin.com |
Full time employees 3040 | Website https://www.biomarin.com | ||
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.